Status:
WITHDRAWN
Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block
Lead Sponsor:
Virginia Commonwealth University
Conditions:
Pain, Postoperative
Pain, Chest
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The goals of this study are as follows: 1. to confirm the safe dosing of ropivacaine for the erector spinae plane block 2. develop a pharmacokinetic profile of the erector spinae plane block, which w...
Eligibility Criteria
Inclusion
- Participant's age is greater than 18 years
- Participant is undergoing a primary coronary artery bypass grafting surgery or heart valve replacement that requires a midline sternotomy incision
- Participant's surgery is being performed by Dr. Vig Kasirajan
Exclusion
- Diagnosis of cirrhosis, hepatitis, primary sclerosing cholangitis
- Abnormal liver function tests demonstrated by lab results
- Allergy to lidocaine, ropivacaine, or midazolam
- Morbid obesity, defined as body mass index greater than 40
- Existing skin neuropathy on the chest or back
- Body weight less than 50 kg
- Participant is not able to provide verbal feedback, such as when the participant develops altered mental status or requires prolonged mechanical ventilation and sedation
- Participant remains intubated on post-operative day 1
- Pregnant women
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03874806
Start Date
July 1 2019
End Date
December 31 2020
Last Update
July 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298